Urinary Incontinence Market Size was valued at USD 11.35 billion in 2022. The Urinary Incontinence market industry is projected to grow from USD 12.06 Billion in 2023 to USD 18.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% during the forecast period (2023 - 2032). Major reasons influencing the market growth include the rising malignancies in the urinary tract or reproductive organs, increased patients with urethral obstructions and UTIs, and the fast-expanding geriatric population. A urinary catheter is a semi-flexible tube used to empty the urine bladder. These catheters are made from various materials, including silicon, rubber, and plastic. Urinary catheter use is advised by doctors in the event of urine incontinence (UI), urinary retention, prostate surgery, or other illnesses like dementia, multiple sclerosis, or spinal cord damage, thus driving the growth of the urinary incontinence market. These are just a few of the market drivers that are driving the market.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In February 2024, BlueWind Medical announced that its Revi implantable Tibial NeuroModulation (iTNM) device for urge urinary incontinence (UUI) was now available in Springfield, Ohio, US. The Revi implant is activated by patients using a lightweight wireless wearable placed around the ankle.
In February 2024, a startup from Columbus called Avation Medical Inc. was able to raise $22M is launch Vivally System, its bladder control device in wearables. It can be worn as an ankle supporter and sends mild electric signals up the leg through an app.
In January 2024, Boston Scientific announced that they had reached an agreement to acquire Axonics, Inc., a medical technology firm specializing mainly in the production and sale of sacral neuromodulation (SNM) devices used for treating incontinence arising from urine or feces. As such, the acquisition will enhance the overall performance of Boston Scientific’s urology portfolio over the next few years.
In May 2023, MedTech Elidah introduced ELITONE URGE , which is a non-invasive treatment option for urge incontinence among other OAB patients and also builds on their experience with stress urinary incontinence products for overactive bladder syndrome known for giving relief to patients suffering from overactive bladders.
Axonics’ latest development, which was approved by Health Canada in December 2022, happens to be its rechargeable fourth-generation SNM system useful for curing women’s SUI.
In May 2022, BlueWind Medical Ltd. closed a USD 64 million Series B funding round, which led to the development of an innovative RENOVA iStim implantable tibial neuromodulation device being investigated as a potential treatment choice for urgency incontinence alone or with urinary urgency and/or frequency.
The market for urinary incontinence devices is expanding as urological illnesses become more common and sophisticated incontinence devices are developed. The market for urinary incontinence devices is expanding due to an older population that is more susceptible to urological issues, an increase in the demand for minimally invasive procedures, and other factors. In addition, more individuals with urine incontinence are anticipated to abandon conventional practices soon. The prevalence of associative urological illnesses is rising, which helps the market grow. Thus, this factor is driving the market CAGR.
One of the main variables projected to fuel product demand ly is the rising prevalence of urological illnesses, such as urine retention, cystitis, benign prostatic hyperplasia, urinary incontinence, and kidney stones that cause bladder dysfunction. The market demand for these goods is anticipated to increase due to the growing number of patients who need catheterization for the management and drainage of urine. For instance, according to the National Health Service (NHS) in England, about 34% of women and about 61% of men suffer from disorders affecting the lower urinary tract. According to Phoenix Physical Therapy, 200 million people ly are reportedly impacted by UI. Thus, the need for urinary catheters for post-operative convenience has increased due to the rising incidence of urological dysfunctions and associated procedures. During the anticipated time frame, this is anticipated to fuel market expansion. The causes of urinary retention are more frequent neurological disorders, posterior urethral strictures, and bladder-neck obstructions. When the essential requirements for reimbursement are satisfied, intermittent catheterization is reimbursed by Medicare and Medicaid. The Medicaid program pays a patient for 120 intermittent catheters per month. While the Medicare program only permits reimbursement for up to 200 sterile and single-use intermittent catheters per month, the reimbursement includes straight, code, catheter kits, and various brands with hydrophilic & antimicrobial coatings. Thus, it is anticipated that this aspect will accelerate Urinary Incontinence market revenue ly.
The Urinary Incontinence market segmentation, based on type includes, urge incontinence, stress incontinence, overflow incontinence, functional incontinence. The stress incontinence segment held the majority share in 2022 in the Urinary Incontinence market data. This is explained by the high prevalence of stress urinary incontinence among women worldwide. According to epidemiological research on stress urinary incontinence in women, 50% of those with urinary incontinence also have symptoms of stress incontinence.
The Urinary Incontinence market segmentation, based on devices, Includes Electrical Stimulation Devices, Foley Catheters, Antimicrobial Foley Catheters, Urethral Bulking Agents. The foley catheter segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. A medical tool used to empty the bladder is a foley catheter. It provides a practical substitute for a catheter that keeps draining. For individuals with spinal cord injuries and neurogenic bladder issues, foley catheterization is the gold standard for bladder emptying. Indwelling catheters are not recommended in favor of these devices because they frequently cause UTIs. The segment is partly expanding because these catheters are covered by Medicaid and Medicare programs, hence contributing in the growth of the urinary incontinence market.
Figure 1 Urinary Incontinence Market, by Devices, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Urinary Incontinence market accounted for USD 5.198 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The key factor driving the regional market is the increased prevalence of specific disorders such as bladder blockage, UI, benign prostate hyperplasia (BPH), urine retention, and bladder cancer. The National Association for Continence reports that overactive bladder (OAB) and urinary urgency are frequently experienced by adults 40 and older. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.
Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 URINARY INCONTINENCE MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Urinary Incontinence market accounts for the second-largest market share. The urinary incontinence sling market accounted for the majority of the market value in Europe. The market for urinary incontinence slings offers both male and female slings. This market is declining as more people become aware of the risks associated with female urinary incontinence slings. Moreover, UK Urinary Incontinence market held the largest market share, and the Germany Urinary Incontinence market was the fastest growing market in the region.
Asia Pacific Urinary Incontinence Market is expected to grow at the fastest CAGR from 2023 to 2032. The rising incidence of spinal cord injury, BPH, and UTI drive the regional market. The most common infectious disease in this area is UTI. It imposes a heavy financial cost on society and is linked to high morbidity and mortality rates, especially in hospitals. The market in the Asia Pacific is therefore being driven by an increase in UTI risks, particularly in older women, constipation, vaginal deliveries, parity, obesity, surgery, and chronic respiratory issues. Further, the China Urinary Incontinence market held the largest market share, and the India Urinary Incontinence market was the fastest-growing market in the region.
Urinary Incontinence Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Urinary Incontinence market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Urinary Incontinence industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Urinary Incontinence industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Urinary Incontinence industry has provided medicine with some of the most significant benefits. The Urinary Incontinence market major player such as NeoTract Inc, Promedon Cook Medical Inc., R. Bard Inc., Coloplast Corp, Boston Scientific Corporation, Ethicon US LLC.
Boston Scientific Company ("BSC") is a biomedical/biotechnology engineering company and a manufacturer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral treatments, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. BSC was founded in Delaware. The Taxus Stent, a drug-eluting stent used to open blocked arteries, was created by Boston Scientific, renowned for this achievement. In February 2019, Boston Scientific unveiled a revision of the mesh sling system, a surgical device used to treat male patients with stress urinary incontinence. Moreover, the surgical mesh is used to stabilize the urethra neck and treat stress incontinence (SUI).
Atlantic Therapeutics produces professional and consumer medical devices, accompanying software, apps, and linked health technologies to treat all forms of incontinence, sexual health dysfunctions, and other related problems by enhancing pelvic floor muscles and regulating pelvic floor nerves. In February 2020, Atlantic Therapeutics declared that the US Food and Drug Administration (FDA) had approved INNOVO, a non-invasive, wearable device with a track record of clinical success, for over-the-counter (OTC) use in treating stress urinary incontinence (SUI) in adult females.
Key Companies in the Urinary Incontinence market includes
Urinary Incontinence Industry Developments
November 2020 BladderCell started a clinical trial for the bioelectric treatment of urine incontinence.
May 2020 Two new kinds of prosthetic urinary sphincters from Rigicon have been released the ContiClassic and ContiReflex variants.
March 2019 Coloplast Corporation and Premier Inc., a healthcare provider based in the United States, agreed to a three-year purchase agreement for Coloplast's catheter product portfolio. With its integrated supply chain, advising, and data analytics solutions, Premier Inc. has a network alliance of around 4,000 US hospitals that might be used to expand Coloplast's relationships at a cheaper cost.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)